Development and validation of nomograms for prediction of overall survival and cancer-specific survival of patients with Stage IV colorectal cancer

Jieyun Zhang1,2,†, Zhe Gong1,2,†, Yiwei Gong1,2,†, and Weijian Guo1,2,*

1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China, and 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China

Abstract

Background: Surgical resection of patients with resectable Stage IV colorectal cancer (CRC) is regarded as first choice if possible. However, its influence on overall survival (OS) has not been thoroughly explored. In this study, we aimed to construct nomograms to help predict 1-, 3- and 5-year OS rate and colorectal cancer-specific survival (CCSS) rate.

Methods: A total of 2996 cases who underwent primary and metastatic resection were selected in the study from surveillance, epidemiology and end results (SEER) database. About 48 Stage IV CRC patients after resection from the Fudan University Shanghai Cancer Center (FUSCC) were assigned as an independent external validation group. Log-rank and multivariate Cox regression analysis were used. The competing-risks model was used to estimate the cumulative incidence of death. Nomograms were built for prediction of OS and CCSS after surgical resection in patients with Stage IV CRC.

Results: The 1-, 3- and 5-year probabilities of OS were 76.6%, 41.4% and 23.2%, respectively. The 1-, 3- and 5-year colorectal cumulative incidence of death were 23.0%, 54.9% and 71.3%, respectively. The calibration curves for probability of 1-, 3- and 5-year OS and CCSS showed optimal agreement between nomogram prediction and actual observation, and the Harrell’s C-indexes for the nomograms to predict OS and CCSS were 0.662 and 0.650, respectively. For FUSCC validation set, the C-index for this model to predict OS was 0.657.

Conclusion: Nomograms for prediction of OS and CCSS of patients with Stage IV CRC who underwent primary and metastatic resection were built. Performance of the model was excellent. These nomograms may be helpful for patients and physicians when making a decision.

Key words: predictive tool, nomogram, Stage IV CRC, overall survival, colorectal cancer-specific survival

Introduction

Colorectal cancer (CRC) was predicted to earn the fourth highest rate of incidence among all cancers in 2015 in the USA, with over 130,000 new cases expected (1). Unfortunately, 20% patients with newly diagnosed CRCs have presented with metastatic disease. The most common metastatic sites are the regional lymph nodes, liver and lungs. Since the venous drainage of the intestinal tract is via the portal system, the first site of hematogenous dissemination is usually...
liver, followed by lungs, bone and many other sites, including (rarely) brain.

Over the past 10 years, with the development of chemotherapy as well as the molecular target agents, in combination with improved surgical techniques, outcomes in patients with metastatic CRC have greatly improved. In an attempt to prolong the survival rate of patients with disseminated CRC, there is consensus that complete (R0) resection is the only curative option in the treatment of patients with CRC liver metastasis (2). What’s more, pulmonary metastasectomy has become a widely accepted practice when metastasis goes to the lung (3).

Five-year overall survival (OS) rates up to 58% have been reported by specialized centers after resection of the liver and primary lesion (4). However, surgery is accompanied with risks of post-operative morbidity and more commonly, high risk of recurrence. Postoperative complications following surgery for CRC are not only associated with poor short-term outcomes, but also with worse long-term outcomes (5). Serious postoperative morbidity includes bile leakage and associated peri-hepatic abscess in liver metastasis resection. As for recurrence, it is reported that ~60% of patients develop early second metastatic recurrence within 3 years after the first liver resection (6). Thus, perioperative care and appropriate surgery candidate selection is of great clinical significance, which would result in morbidities rates and better life quality. Therefore, it would be desirable to develop a practical and easy-to-use scoring system to screen in patients with better overall physical conditions to undergo the surgery process and hopefully, enjoy the benefit from it.

Since patients of Stage IV CRC might die of causes unrelated to cancer itself, as a result, OS might fail to accurately represent a patient’s long-term survival rate attributed to CRC. Thus, excluding other causes of death is necessary when estimating colorectal cancer-specific survival (CCSS).

Nomograms have been widely used as practical tools in clinical oncology for quantifying risks by taking important prognostic factors into account and models are built upon that, where overall probability of a specific outcome for any individualized patient can be calculated by adding scores up.

In this study, we aimed to develop a comprehensive nomogram involving a larger population with all situations of metastasis (not just the liver) to estimate the long-term OS and CCSS, thus providing information to patients for reference.

### Patients and methods

#### Screening and data processing

Data were collected from the SEER program of the National Cancer Institute. The criteria of eligible patients were as followed: aged 18–85 years old at diagnosis; known time of diagnosis between 1 January 2004 and 31 December 2012; diagnosis with colorectal carcinoma as the first and only cancer diagnosis; diagnosis confirmed in a patient who is alive and not from a death certificate or autopsy; surgical treatment with both original and metastatic site resected; tumor grade is pathologically confirmed; staging is defined according to American Joint Committee on Cancer (AJCC) Seventh edition and Stage IV is included; histology confirmed as mucinous adenocarcinoma, signet ring cell carcinoma, adenocarcinoma except mucinous adenocarcinoma which was categorized as ‘other adenocarcinoma’ and others. Patients who were diagnosed before 2004 were not included because AJCC got the updated edition at 2004. Additionally, to make sure there is adequate follow-up time, we excluded the patients diagnosed after 2012.

A total of 2996 patients were included after the screening. American Indian/Alaskan Native and Asian/Pacific Islanders were recorded as ‘other’ under race. Age was transformed into categorical variables based on recognized cut off values. For the analysis based on carcinoembryonic antigen (CEA) level, we selected patients for whom the lab result of CEA was coded as positive/elevated or negative/normal in the database. As to create a group of patients with whom the positivity or negativity was known, we excluded patients whose CEA were coded as unknown/undetermined/equivocal. We classified patients into two categories: (1) positive for CEA and (2) negative for CEA.

There were two external validation sets used to validate the nomogram, 749 patients from SEER data were selected as SEER validation cohort randomly. In addition, 48 CRC patients diagnosed between 2006 and 2018 who underwent both primary and metastatic resection from FUSCC were assigned as FUSCC validation cohort. None of these patients had synchronous benign disease or cancers. Patients without sufficient clinicopathological information, or patients suffered from more than one primary tumors, or those died within 2 months of surgery, were all excluded. Our study was approved by the Fudan University Shanghai Cancer Center (FUSCC) ethics committee.

#### Statistical analysis and construction of the nomogram

In order to validate a competing-risks nomogram, the selected SEER patients were divided into a training ($n = 2247$) cohort and a validation ($n = 749$) cohort randomly. Time expanding from tumor diagnosis to death was used to calculate OS. If date of last contact was after 2012, then date of last follow-up was calculated as 31 December 2012. Log-rank tests were applied to determine univariate prognostic factors. A multivariate Cox proportional hazards model was applied to estimate the independent effects of the univariate prognostic factors on OS. The independent prognostic factors determined by the multivariate analysis were used to construct the nomogram for OS. The cumulative incidence function (CIF) was used to assess the probability of colorectal cancer-specific mortality (CCSM) and death from other causes. CIF was calculated by Gray’s test between category groups. Deaths due to other causes were viewed as competing-risk events.

Figure 1. Flow chart for the surveillance, epidemiology and end results data screening.
which preclude the possibility of death resulting from CRC. In the Cox regression model analyzing the cause-specific regression, patients who died from other causes were excluded at the end of follow-up. Integrating the associated risk factors, nomograms were developed to predict the OS and cancer-specific survival (CSS) 1, 3 or 5 years after diagnosis. All *P* values are two-sided, and those <0.05 were considered statistically significant on the basis of the large number of patients.

**Validation and calibration of the nomogram**

To decrease bias, the nomograms were subjected to internal validation in the cohort and external validation in SEER validation cohort and independent FUSCC cohort, respectively. To create a calibration diagram, the marginal estimate versus model average predictive probability was used. In a perfectly calibrated model, predictive rates would fall on a 45-degree diagonal line. The interpretation of an index of probability of concordance (C-index) between predicted probability and actual outcome was used so as to evaluate the predictive ability and discrimination of the model. The value of the C-index should fall between 0.5 and 1.0, with 0.5 indicating random chance and 1.0 indicating a perfect discriminative ability. Identification of independent prognostic factors was conducted using Stata. The construction, validation and calibration of the nomograms were built on R version 3.1.2 software. The R packages cmprsk and rms and a C-index function for competing-risks model were used for modeling and developing the nomograms.

### Results

The patients with Stage IV CRC in training cohort (N = 2247) and surveillance, epidemiology and end results (SEER) validation cohort (N = 749) were collected from the SEER cancer registry program. The SEER database covers ~26% of the US population, and the characteristics of the SEER population are comparable to the general US population. The flow chart for SEER data selection is shown in Fig. 1. The clinicopathological characteristics of selected patients are listed in Table 1. The median survival times of the training cohort and SEER validation cohort were 20 months (9–38 months) and 21 months (7–36 months), respectively. By the end of

### Table 1. Patients’ demographics and clinical characteristics SEER 2004–12 (n = 2996)

| Variable                  | All patients | Training cohort | SEER validation cohort |
|---------------------------|--------------|-----------------|------------------------|
|                           | No. | %  | No. | %  | No. | %  |
| Race                      |     |    |     |    |     |    |
| White                     | 2352 | 78.5 | 1779 | 79.17 | 573 | 76.5 |
| Black                     | 387  | 12.92 | 282  | 12.53 | 105 | 14.02 |
| Others*                   | 257  | 8.58 | 186  | 8.58 | 71  | 9.48 |
| Age                       |     |    |     |    |     |    |
| 18–39                     | 184  | 6.14 | 140  | 6.23 | 44  | 5.87 |
| 40–59                     | 1245 | 41.46 | 928  | 41.3 | 317 | 42.32 |
| >60                       | 1567 | 52.3 | 1179 | 52.47 | 388 | 51.8 |
| Sex                       |     |    |     |    |     |    |
| Female                    | 1526 | 50.93 | 1134 | 50.47 | 392 | 52.34 |
| Male                      | 1470 | 49.07 | 1113 | 49.53 | 357 | 47.66 |
| T                         |     |    |     |    |     |    |
| T1                        | 40   | 1.34 | 33   | 1.47 | 7   | 0.93 |
| T2                        | 96   | 3.2 | 74   | 3.29 | 96  | 3.2 |
| T3                        | 1878 | 62.68 | 1390 | 61.86 | 488 | 65.15 |
| T4                        | 982  | 32.78 | 750  | 33.38 | 232 | 30.97 |
| N                         |     |    |     |    |     |    |
| N0                        | 527  | 17.59 | 409  | 18.2 | 118 | 15.75 |
| N1                        | 1129 | 37.68 | 843  | 37.32 | 286 | 38.18 |
| N2                        | 1340 | 44.73 | 995  | 44.28 | 345 | 46.06 |
| M1a                       | 711  | 23.73 | 529  | 23.54 | 182 | 24.3 |
| M1b                       | 2285 | 76.27 | 1718 | 76.46 | 567 | 75.7 |
| CEA                       |     |    |     |    |     |    |
| Negative                  | 709  | 23.66 | 540  | 24.03 | 169 | 22.56 |
| Positive                  | 2287 | 76.34 | 1707 | 75.97 | 580 | 77.44 |
| Grade                     |     |    |     |    |     |    |
| Well differentiated       | 99   | 3.3 | 78   | 3.47 | 21  | 2.8 |
| Moderately differentiated  | 2077 | 69.33 | 1562 | 69.51 | 515 | 68.76 |
| Poorly differentiated      | 712  | 23.77 | 526  | 23.41 | 186 | 24.83 |
| Undifferentiated          | 108  | 3.6 | 81   | 3.6 | 27  | 3.6 |
| Histology                 |     |    |     |    |     |    |
| Other Adenocarcinoma      | 2681 | 89.49 | 2010 | 89.45 | 671 | 89.59 |
| Mucinous adenocarcinoma    | 264  | 8.81 | 202  | 8.99 | 62  | 8.28 |
| Signet ring cell carcinoma| 51   | 1.7 | 35   | 1.56 | 16  | 2.14 |

*Including American Indian or Alaska Native and Asian or Pacific Islander.*
Factors associated with overall survival

We used Log-rank method to evaluate OS for these patients. The results showed that 1-, 3- and 5-year OS were 76.53%, 41.44% and 23.24%, respectively. In univariate survival analysis, except gender, these variables, including age, race, histology type, CEA level, TMN stage and grade were proved to be significantly correlated with OS ($P < 0.001$ for all except race and $P < 0.05$ for race). These prognostic factors that were identified as statistically significant in univariate analysis were further included in the multivariate analysis (Cox proportional hazards model) and were further confirmed to be independently associated with OS (Table 3). These factors were finally included in the nomograms and helped to build nomograms.

A weighted total score added up from these variables was used to estimate and predict 1-, 3- and 5-year OS of patients.

Cancer-specific survival and competing-risk analysis

At 1, 3 and 5 years after diagnosis, the cumulative incidences of death resulting from colorectal carcinoma (CIDCC) of the training cohort were 23.0%, 54.9% and 71.2%, respectively, while the cumulative incidences of death resulting from other causes were 2.48%, 4.7% and 6.1%, respectively. Estimates of probabilities of death resulting from CRC and other causes according to patient and tumor characteristics are listed in Table 4. Age and grade status showed significant associations with probability of death. A significant association between TMN stage and cumulative incidence of death was observed only within the CRC death cohort ($P < 0.001$). There was no statistical relationship between probability of death between different races and gender. All variables significantly correlated with CIDCC were used to build the nomogram to predict 1-, 3- and 5-year CSS rate.

Nomogram

The nomogram for predicting 1-, 3- and 5-year OS were built based upon the reduced multivariate models in the training cohort (Fig. 1), while the nomogram for predicting the CSS was built upon competing-risk analysis (Fig. 2). For model validation, an external validation procedure was also adopted. As shown in Table 1, in the training cohort, the internal Harrell’s C-indexes for the nomograms to predict OS and CSS were 0.662 and 0.630, respectively (95% CI 0.647–0.676 and 0.633–0.666). In SEER validation cohort, the external C-indexes of OS and CSS were slightly higher: 0.666 and 0.669 (95% CI 0.639–0.693 and 0.641–0.697). In FUSCC validation cohort, the external C-index of OS was 0.657 (95% CI 0.544–0.770). The tiny difference between the internal and external validation C-index implied that these models were quite satisfactory. The internal calibration plots are presented in Fig. 3, revealing an excellent correlation in OS and CSS between the nomogram predicted and outcome observed. When it comes to the clinical application of this nomogram, we can take a patient who has recently been diagnosed of Stage IV CRC as an example. This patient is an African American who is 63 years old with positive CEA level. Biopsy showed poorly differentiated cells and signet ring cell type. CT showed hepatic metastasis and then the stage was evaluated as T3M1bN2. He wonders the prognosis of his situation and whether he could have both the primary site and liver lesion resected. As his physician, you refer to these two nomograms and add the individual scores up. The result shows that he has got 41.56 points and 41.31 points in OS and CSS nomogram. The predictive 1-year OS rate is slightly lower than 40%, and 1-year CSS rate is a bit lower than 50%. The difference between these two figures could possibly be explained by the serious complications due to surgery and thus, rendering lower OS compared with CSS, which explains why some physicians prefer conservative management rather than radical surgery. Furthermore, there is little hope that he can survive the third year, and 3-year CSS rate is 10%. Through this practical tool, the physician can stratify this patient and give him personal advice.

Discussion

Patients with late stage CRC has very low median survival and 5-year OS rate if they did not receive any treatment (7). Resection is still considered as the preferred therapy for potential cure by most
physicians (8). However, the definition and criteria for ‘resectable’ is still not well determined. There are plenty of researches discussing the extension of resection criteria (9,10). However, surgery could only be considered if, R0 resection is thought possible at the end of treatment. Those are the factors should be taken into consideration regarding whether to be operated on: the anatomical distribution of the disease; the residual functional volume of the metastatic organ; the management of the primary site; the timing and role of neoadjuvant chemotherapy, and whether all lesions can be resected successfully at one setting (11).

Several clinicopathological characteristics were proven independent prognostic factors for both OS and CSS in the present study, including age, histology type, grade, stage and CEA level. One exception is race. Race type has influence on OS, while does not affect CSS. Histology type exerts great effect on the survival rate. From the data on cumulative incidence of death, mucinous adenocarcinoma and signet ring cell cancer have far more percentage of death compared with other type of adenocarcinoma. In 1-year follow-up, the cumulative incidence of death of signet ring type is 52.3% compared with that of the other adenocarcinoma, which is 22.0%. When viewing three-year follow-up, the CIF increases to 76.9% among signet ring cell cancer, and 53.0% and 70.6% in adenocarcinoma and mucinous adenocarcinoma, respectively.

Previous data have described that CEA level has a sensitive indication of worse prognosis and that increase in CEA is an independent predictor of poor survival. In this study, positive CEA had a hazard ratio of 1.35 compared with negative CEA and showed distinct difference in cancer-specific mortality, which coincide with previous study. Fine and Gray modeling approach was adopted to construct models and the nomogram. The main advantage of the sub distribution methodology is that through simply model fitting we can see the direct effect of each covariate on cumulative incidence. The log-rank test and Cox proportional hazards regression were used for calculating the independent prognostic factors of OS. However, hazard ratios as obtained by cause-specific Cox regression analyses do not directly quantify the ability of the single markers to predict the unconditional absolute risk of an event of

Table 3. Univariate and multivariate survival analysis for colorectal cancer overall survival (OS) in the training cohort. Surveillance, epidemiology and end results 2004–12 (n = 2247)

|                | 1-Year OS (%) | 3-Year OS (%) | 5-Year OS (%) | Log-rank $\chi^2$ | $P$ | Hazard ratio | 95% CI | $P$ |
|----------------|---------------|---------------|---------------|-------------------|-----|--------------|--------|-----|
| All            | 76.55         | 41.44         | 23.24         |                   | 0.12| 0.727        |        |     |
| Sex            |               |               |               |                   |     |              |        |     |
| Female         | 75.76         | 41.63         | 23.09         |                   |     |              |        |     |
| Male           | 77.35         | 41.24         | 23.38         |                   |     |              |        |     |
| Age            |               |               |               |                   |     |              |        |     |
| 18–39          | 86.79         | 52.78         | 34.68         |                   | 85.7| <0.001       |        |     |
| 40–59          | 85.45         | 50.48         | 29.49         |                   | 1.22| 0.95–1.56    | 0.122  |     |
| >60            | 68.0          | 32.69         | 16.88         |                   | 2.08| 1.64–2.65    | <0.001 |     |
| T              |               |               |               |                   |     |              |        |     |
| T1             | 90.30         | 62.68         | 37.97         |                   | 52.44| <0.001      |        |     |
| T2             | 88.79         | 59.41         | 27.32         |                   | 1.1 | 0.63–1.92    | 0.746  |     |
| T3             | 80.16         | 45.25         | 25.93         |                   | 1.26| 0.78–2.04    | 0.347  |     |
| T4             | 67.65         | 31.01         | 16.83         |                   | 1.67| 1.02–2.71    | 0.040  |     |
| N              |               |               |               |                   |     |              |        |     |
| N0             | 82.49         | 55.13         | 30.07         |                   | 52.08| <0.001      |        |     |
| N1             | 79.78         | 44.64         | 27.39         |                   | 1.22| 1.04–1.43    | 0.014  |     |
| N2             | 71.32         | 33.18         | 17.13         |                   | 1.55| 1.33–1.81    | <0.001 |     |
| M              |               |               |               |                   |     |              |        |     |
| M1a            | 85.41         | 47.87         | 26.92         |                   | 23.09| <0.001      |        |     |
| M1b            | 74.12         | 39.57         | 22.21         |                   | 21.52| <0.001      |        |     |
| CEA            |               |               |               |                   |     |              |        |     |
| Negative       | 79.39         | 51.23         | 31.73         |                   | 21.52| <0.001      |        |     |
| Positive       | 75.63         | 38.30         | 20.46         |                   | 55.23| <0.001      |        |     |
| Grade          |               |               |               |                   |     |              |        |     |
| Well differentiated | 82.95       | 46.53         | 22.43         |                   | 1.35| 1.19–1.54    | <0.001 |     |
| Moderately differentiated | 80.98   | 45.99         | 25.44         |                   | 0.98| 0.74–1.29    | 0.864  |     |
| Poorly differentiated | 63.76   | 28.61         | 17.50         |                   | 1.36| 1.02–1.82    | 0.035  |     |
| Undifferentiated | 66.93        | 31.62         | 21.68         |                   | 1.3 | 0.87–1.93    | 0.197  |     |
| Histology      |               |               |               |                   |     |              |        |     |
| Other Adenocarcinoma | 77.8       | 43.25         | 24.48         |                   | 44.24| <0.001      |        |     |
| Mucinous adenocarcinoma | 70.66     | 28.09         | 14.23         |                   | 1.2 | 1.01–1.44    | 0.042  |     |
| Signet ring cell carcinoma | 41.9      | 14.37         | 4.79          |                   | 1.46| 1–2.12       | 0.050  |     |
| Race           |               |               |               |                   | 8.96| 0.0113       |        |     |
| White          | 76.28         | 42.38         | 24.43         |                   |     |              |        |     |
| Black          | 76.18         | 33.65         | 14.75         |                   |     |              |        |     |
| Other*         | 79.68         | 43.56         | 23.56         |                   | 1.31| 1.13–1.54    | <0.001 |     |

*Including American Indian or Alaska Native and Asian or Pacific Islander.
interest, failing to identify prognostic factors of CSS due to the possibility of biased results (12). Therefore, a competing-risks model was introduced. A competing risk was defined when the occurrence of an event either precludes the occurrence of another event under evaluation or altered the probability of occurrence for the other event (13).

Since many patients who were diagnosed of Stage IV CRC have the concern about whether or not running the risk of surgery in exchange for a longer life, there is great urge to build a scoring system for reference. There are several nomograms already developed associated with CRC, including but not limited to prediction of the oncological prognosis, the short-term outcome of treatments, such as surgery or neoadjuvant chemo/radiotherapy, and the possible future development of CRC (14, 15, 14–15). Since variables differ substantially between early stage and metastatic CRC, the nomogram usually focuses on only one aspect, either Stage I-III or Stage IV CRC (16).

There have been previous reports of nomograms predicting the prognosis after resection of liver metastases (15, 17), which included both synchronous, metachronous liver metastases and a variety of clinical settings, with the C-indexes being ~0.6, relative low ones. Most of these models were built upon a relative small population, for example, 727 cases in Beppu T’s (18) nomogram and 578 cases in Kanemitsu et al’s (19) nomogram.

Not until 2015 was the first nomogram predicting the prognosis of Stage IV CRC after curative resection developed. They built nomograms predicting the prognosis of Stage IV patients with metastasis to organs other than the liver, such as the peritoneum, lung or distant lymph nodes. In this study, Kawai (20) enrolled 1133 patients who had Stage IV CRC and underwent curative surgery from January 1997 to December 2007. He built a nomogram to predict disease free survival and OS with C-indexes of 0.62–0.64. His nomogram of prediction of OS rate included four variables: post-operation CEA level, T and N status and peritoneal dissemination. However, the majority

| Table 4. 1-, 3- and 5-year cumulative incidences of death among patients in the training cohort. SEER 2004–12 (n = 2247) |
|---------------------------------------------------------------|
| **Cumulative incidence of death resulting from colorectal cancer** | **Cumulative incidence of death resulting from other causes** |
|                  | 1-Year (%) | 3-Year (%) | 5-Year (%) | P    | 1-Year (%) | 3-Year (%) | 5-Year (%) | P    |
| All              | 23.04      | 54.94      | 71.27      | 0.741 | 2.48       | 4.75       | 6.12       | 0.656 |
| Sex              |            |            |            |       |            |            |            |       |
| Female           | 24.1       | 55.0       | 71.8       |       | 2.1        | 4.5        | 5.7        |       |
| Male             | 21.9       | 54.9       | 70.7       |       | 2.9        | 5.0        | 6.6        |       |
| Age              |            |            |            | <0.001|            |            |            |       |
| 18–39            | 12.4       | 42.3       | 60.3       |       | 1.5        | 5.3        | 5.3        |       |
| 40–59            | 13.9       | 47.2       | 66.8       |       | 1.1        | 2.6        | 3.9        |       |
| >60              | 31.5       | 62.5       | 76.0       |       | 3.7        | 6.3        | 7.9        |       |
| T                |            |            |            | <0.001|            |            |            | 0.77  |
| T1               | 6.5        | 30.1       | 50.0       |       | 3.2        | 7.2        | 12.0       |       |
| T2               | 12.4       | 36.4       | 66.1       |       | 0          | 4.9        | 6.9        |       |
| T3               | 19.4       | 51.6       | 69.2       |       | 2.4        | 4.3        | 5.5        |       |
| T4               | 31.8       | 64.6       | 76.9       |       | 2.9        | 5.5        | 6.8        |       |
| N                |            |            |            | <0.001|            |            |            |       |
| N0               | 15.7       | 40.2       | 61.2       |       | 2.9        | 5.3        | 9.1        | 0.106 |
| N1               | 20.2       | 51.7       | 67.5       |       | 2.1        | 4.8        | 5.8        |       |
| N2               | 28.4       | 63.5       | 78.3       |       | 2.7        | 4.5        | 5.1        |       |
| M                |            |            |            | <0.001|            |            |            | 0.525 |
| M1a              | 14.7       | 47.3       | 67.8       |       | 1.9        | 5.9        | 5.9        |       |
| M1b              | 25.3       | 56.9       | 72.4       |       | 2.7        | 4.6        | 6.0        |       |
| CEA              |            |            |            | <0.001|            |            |            | 0.795 |
| Negative         | 19.6       | 45.5       | 62.9       |       | 2.3        | 4.2        | 5.9        |       |
| Positive         | 24.1       | 57.9       | 74.0       |       | 2.5        | 4.9        | 6.2        |       |
| Grade            |            |            |            | <0.001|            |            |            | 0.027 |
| Well differentiated | 13.1     | 49.5       | 65.8       |       | 4.0        | 4.0        | 11.8       |       |
| Moderately differentiated | 18.5   | 49.9       | 68.7       |       | 2.4        | 5.2        | 6.4        |       |
| Poorly differentiated | 35.9 | 68.6       | 78.6       |       | 2.7        | 3.9        | 4.5        |       |
| Undifferentiated; | 35.1   | 66.9       | 76.3       |       | 1.2        | 3.1        | 3.1        |       |
| Histology        | 0.005      |            |            |       | 0.025      | 0.050      | 0.063      | 0.88  |
| Other Adenocarcinoma | 22.0  | 53.0       | 69.9       |       | 0.016      | 0.016      | 0.034      |       |
| Mucinous adenocarcinoma | 28.4 | 70.6       | 82.5       |       | 0.057      | 0.087      | 0.087      |       |
| Signet ring cell carcinoma | 52.4 | 76.9       | 86.5       |       |            |            |            |       |
| Race             | 0.258      |            |            |       | 0.27       | 0.48       | 0.62       | 0.742 |
| White            | 23.3       | 54.1       | 70.1       |       | 2.7        | 4.8        | 6.2        |       |
| Black            | 23.7       | 62.7       | 80.3       |       | 2.6        | 4.7        | 5.4        |       |
| Others           | 19.7       | 51.9       | 69.7       |       | 0.6        | 4.5        | 6.8        |       |

Abbreviation: SEER = Surveillance, Epidemiology and End Results.

*Including American Indian or Alaska Native and Asian or Pacific Islander.
patients are Asians in their study. What’s more, studies conducted in one single institution often do not have sufficient power to figure true prognostic factors for CRC because of complications and short follow-up periods. As to extend the usage of this predictive tool in the US population, we enrolled more candidates, wider variety of races and took two more variables into consideration, histology types and grade. The population-based SEER cancer registries have made the estimation of more prognostic factors based on a larger sample possible that reduce selection biases (21). Results from a population-based cohort are more reliable and are probably to be more applicable to larger population. Cumulative incidence of death resulting from CRC and other causes can be calculated based on the recorded cause of death. In conclusion, the strengths of our present study include the population-based design, long-term follow-up and sufficient sample size.

Despite advantages in our study, there are some limitations in our study. First, most patients once received chemotherapy or radiation, however, the type, number of chemotherapy/radiation regimens received and their response to treatment is not available in SEER database. Second, to ensure a sufficient follow-up period, this study included relatively old cases; what’s more to enroll as many patients as possible, the study period was relatively long. During this period, surgery technique has improved greatly, and bias might result.

In summary, we developed nomograms to estimate the probability of OS and CSS of Stage IV colorectal carcinoma after
operation based on a large, population-based cohort with long-term follow-up. The nomograms have satisfactory performance in both the training and validation cohorts, and they are potentially effective tools for predicting the prognosis of Stage IV CRC with surgical resection of both primary and metastatic lesion. They will help clinicians to rule in individuals who could benefit most from the operation, thus providing more individualized treatment strategies.

**Acknowledgements**

The authors acknowledge the efforts of the SEER Program tumor registries in the creation of the SEER database. The interpretation of these data is the sole responsibility of the authors.

**Conflict of interest statement**

None declared.
No specific funding was disclosed.

References
1. Al-Hajeili M, Marshall JL, Smaglo BG. Neoadjuvant treatment for surgically resectable metastatic colorectal cancer. *Oncology (Williston Park)* 2016;30:10–6.
2. Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. *Ann Surg Oncol* 2006;13:1271–80.
3. Benson AR, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. *J Natl Compr Canc Netw* 2014;12:1028–59.
4. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004;239:818–25, 825–827.
5. McArdle CS, McMillan DC, Hole DJ. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. *Br J Surg* 2005;92:1150–4.
6. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. *Ann Surg* 2009;250:440–8.
7. Priesching A. [When is resection of liver metastases indicated?]. *Langenbecks Arch Chir* 1987;372:513–7.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999;230:309–18, 318–321.
9. Amri R, Bordeianou LG, Sylla P, Berger DL. Variations in metastasis site by primary location in colon cancer. *J Gastrointest Surg* 2015;19:1522–7.
10. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. *Oncologist* 2008;13:51–64.
11. Massacesi C, Norman A, Price T, et al. A clinical nomogram for predicting long-term survival in advanced colorectal cancer. *Eur J Cancer* 2000;36:2044–52.
12. Southern DA, Faris PD, Brant R, et al. Kaplan–Meier methods yielded mis-leading results in competing risk scenarios. *J Clin Epidemiol* 2006;59:1110–4.
13. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. *J Clin Oncol* 2013;31:468–74.
14. Ying HQ, Deng QW, He BS, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. *Med Oncol* 2014;31:305.
15. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975–2012. SEER web-site April 2015.
16. Smith MD, Parks RW. Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. *World J Surg* 2008;32:1108–9.
17. (a) Tez M, Tez S. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. *Ann Surg* 2008;248:141-142, 142; author reply 142; (b) Kawai K, Ishihara S, Yamaguchi H, et al. Nomogram prediction of metachronous colorectal neoplasms in patients with colorectal cancer. *Ann Surg* 2015;261:926-932.
18. Beppu T, Sakamoto Y, Hasegawa K, et al. A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. *J Hepatobiliary Pancreat Sci* 2012;19:72-84.
19. Kanemitsu Y, Kato T. Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. *World J Surg* 2008;32:1097–1107.
20. Kawai K, Sunami E, Yamaguchi H, et al. Nomograms for colorectal cancer: a systematic review. *World J Gastroenterol* 2015;21:11877–86.
21. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. *Cancer* 1997;79:564–73.